|
Characterization of familial Waldenstrom's macroglobulinemia
|
|
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
|
|
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
|
|
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders
|
|
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling
|
|
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders
|
|
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications
|
|
Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia
|
|
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
|
